Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

21. Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder

Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Article Text

2012 Evidence-Based Mental Health

22. Relapse risk after discontinuation of risperidone in Alzheimer's disease. Full Text available with Trip Pro

Relapse risk after discontinuation of risperidone in Alzheimer's disease. Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were (...) then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation.A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs

2012 NEJM Controlled trial quality: predicted high

23. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. Full Text available with Trip Pro

Long-acting risperidone and oral antipsychotics in unstable schizophrenia. Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized trial involving patients with unstable disease.We randomly assigned patients in the Veterans Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized within the previous 2 years or were (...) at imminent risk for hospitalization to 25 to 50 mg of long-acting injectable risperidone every two weeks or to a psychiatrist's choice of an oral antipsychotic. All patients were followed for up to 2 years. The primary end point was hospitalization in a VA or non-VA psychiatric hospital. Symptoms, quality of life, and functioning were assessed in blinded videoconference interviews.Of 369 participants, 40% were hospitalized at randomization, 55% were hospitalized within the previous 2 years, and 5% were

2011 NEJM Controlled trial quality: predicted high

24. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. Full Text available with Trip Pro

Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. Serotonin reuptake-inhibiting (SRI) antidepressants are the only FDA-approved pharmacotherapies for the treatment of posttraumatic stress disorder (PTSD).To determine efficacy of the second-generation antipsychotic risperidone as an adjunct to ongoing pharmacologic and psychosocial treatments for veterans with chronic military-related PTSD.A 6-month, randomized (...) the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (HAMA), Clinical Global Impression scale (CGI), and Veterans RAND 36-Item Health Survey (SF-36V).Change in CAPS scores from baseline to 24 weeks in the risperidone group was -16.3 (95% CI, -19.7 to -12.9) and in the placebo group, -12.5 (95% CI, -15.7 to -9.4); the mean difference was 3.74 (95% CI, -0.86 to 8.35; t = 1.6; P = .11). Mixed model analysis of all time points also showed no significant difference in CAPS score

2011 JAMA Controlled trial quality: predicted high

25. Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking

Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: clozapine shows some improved clinical efficacy over risperidone and zotepine

2011 Evidence-Based Mental Health

26. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline

Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline | Evidence-Based (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Article Text Therapeutics Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics

2011 Evidence-Based Mental Health

27. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews Full Text available with Trip Pro

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews Services on Demand Journal Article (...) Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 1516-3180 Sao Paulo Med. J. vol.128 no.3 São Paulo May 2010 SYSTEMATIC REVIEW Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews Eficácia e segurança dos antipsicóticos atípicos (quetiapina, risperidona, aripiprazol, paliperidona) em

2010 Sao Paulo Medical Journal

28. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial Full Text available with Trip Pro

Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial To evaluate the quality of life, efficacy and safety of Warm-Supplementing Kidney Yang (WSKY) added to risperidone in patients with schizophrenia.A randomized controlled trial.The outpatient and inpatient departments of three hospitals.One hundred and twenty patients with clinically diagnosed schizophrenia with predominantly negative symptoms were (...) included in the study.All 120 patients were randomly assigned to double-blind treatment with WSKY group (n = 60) or placebo group (n = 60) added to risperidone for eight weeks.The efficacy measures included the World Health Organization Quality of Life Scale (WHOQOL-100), the Positive and Negative Syndrome Scale (PANSS), the Social Disability Screening Schedule and the Hamilton Rating Scale for Depression. Safety and tolerability were assessed throughout the trial.The scores of quality of life

2010 EvidenceUpdates Controlled trial quality: predicted high

29. Review: lack of evidence for the optimal dose of risperidone for schizophrenia

Review: lack of evidence for the optimal dose of risperidone for schizophrenia Review: lack of evidence for the optimal dose of risperidone for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lack of evidence for the optimal dose of risperidone for schizophrenia Article Text Therapeutics Review: lack of evidence for the optimal dose of risperidone for schizophrenia Statistics from Altmetric.com Question Question

2010 Evidence-Based Mental Health

30. Review: Is aripiprazole as effective as risperidone in people with schizophrenia?

Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Review: Is aripiprazole as effective as risperidone in people with schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Article Text Therapeutics Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Statistics from Altmetric.com

2010 Evidence-Based Mental Health

31. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Full Text available with Trip Pro

Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Attention deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not ben tested widely. Risperidone has been used to treat ADHD in people with ID, although the evidence for its effectiveness is unclear.To examine the effectiveness of risperidone for the treatment of attention (...) and citation searches were performed in ISI Web of Knowledge.All randomised controlled trials (RCTs), both published and unpublished, in any language, in which children or adults with ADHD and ID were treated with risperidone.Data collection and analyses were planned but not performed due to a lack of suitable studies.Eleven studies were considered but none were suitable for inclusion.There is no evidence from RCTs that risperidone is effective for the treatment of ADHD in people with ID. Prescribing

2009 Cochrane

32. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss Full Text available with Trip Pro

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of branded versus generic risperidone, for patients with schizophrenia, assuming different losses in compliance after generic substitution. Assuming the price of the generic substitute was 40% below

2009 NHS Economic Evaluation Database.

33. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Full Text available with Trip Pro

Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of first-line treatment with long-acting risperidone, olanzapine, or quetiapine for young patients with schizophrenia. The authors concluded that risperidone was cost

2009 NHS Economic Evaluation Database.

34. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine

2008 Evidence-Based Mental Health

35. Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects Full Text available with Trip Pro

Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have

2008 Evidence-Based Mental Health

36. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia (Abstract)

A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation. Empirical evidence has shown that some herbal medicines have suppressive effects on prolactin (PRL) hyperactivities. This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (...) (PGD) with bromocriptine (BMT), a dopamine agonist widely used for PRL-secreting disorders, in the treatment of risperidone-induced hyperprolactinemia. Twenty schizophrenic women who were under risperidone maintenance treatment, diagnosed with hyperprolactinemia (serum PRL levels >50 mug/L), and currently experiencing oligomenorrhea or amenorrhea were selected for the study. Subjects were randomized to additional treatment with PGD (45 g/d) followed by BMT (5 mg/d) or BMT followed by PGD

2008 EvidenceUpdates Controlled trial quality: uncertain

37. Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Article Text Therapeutics Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Statistics from

2008 Evidence-Based Mental Health

38. Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia

Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Article Text Therapeutics Risperidone improves symptoms in people who

2008 Evidence-Based Mental Health

39. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. (Abstract)

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Aggressive challenging behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared flexible doses of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second (...) -generation antipsychotic), and placebo, in the treatment of this behaviour.86 non-psychotic patients presenting with aggressive challenging behaviour from ten centres in England and Wales, and one in Queensland, Australia, were randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29). Clinical assessments of aggression, aberrant behaviour, quality of life, adverse drug effects, and carer uplift (positive feelings about the care of the disabled person) and burden, together with total

2008 Lancet Controlled trial quality: predicted high

40. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Heeg B M, Antunes J, Figueira M L, Jara J M, Marques Teixeira J, Palha A P, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout B A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of long-acting risperidone (LAR) as first-line treatment of schizophrenia compared with conventional haloperidol depot and oral risperidone. The authors concluded that treatment with LAR might be cost

2008 NHS Economic Evaluation Database.